Sunday 18 October 2026
Export HURA’s income statement to Excel — free account
TuHURA Biosciences, Inc.
HURA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.3% and free cash flow fell 70.5%, each against the same quarter a year earlier.
1.76
0.07
−3.83%
Follow HURA
TuHURA Biosciences, Inc. (HURA) P/E ratio
TuHURA Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NRXP NRx Pharmaceuticals, Inc. compare | n/m |
| ENGN enGene Therapeutics Inc compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. compare | n/m |
| FHTX Foghorn Therapeutics Inc. compare | n/m |
| SEER Seer, Inc. compare | n/m |
| ABOS Acumen Pharmaceuticals, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)